Trial Profile
An 8 Week, Randomized, Double-Blind, Parallel Group, Multicenter Trial Comparing the Efficacy and Safety of Oral IPL512,602 [Inflazyme Pharmaceuticals] to Placebo in Subjects With Moderate to Severe Persistent Asthma Inadequately Controlled on Inhaled Corticosteroids
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2014
Price :
$35
*
At a glance
- Drugs IPL 512602 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms CAPSICS
- Sponsors Inflazyme Pharmaceuticals
- 24 Jan 2006 New trial record.